Citi analyst Joanne Wuensch lowered the firm’s price target on Boston Scientific (BSX) to $102 from $130 and keeps a Buy rating on the shares. The firm views the post-earnings selloff as overdone. It sees a buying opportunity at current share levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $112 from $131 at Canaccord
- Spotify, Boston Scientific removed from ‘US 1 List’ at BofA
- Boston Scientific’s Earnings Call Highlights Durable Growth
- Boston Scientific price target lowered to $110 from $132 at BTIG
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!